Adap­ti­m­mune R&D chief Ama­do hits the ex­it amid a top-lev­el shake­up as new CEO tries to re­vive ebbing en­thu­si­asm

Adri­an Raw­cliffe doesn’t have any time to waste in mak­ing over the top team at Adap­ti­m­mune $ADAP, a high pro­file TCR-fo­cused biotech that was once a dar­ling of the I/O crowd, with hy­brid op­er­a­tions in the UK and the US in a ma­jor al­liance with Glax­o­SmithK­line.

Still a few weeks out from ac­tu­al­ly as­sum­ing the CEO ti­tle from founder James No­ble, Raw­cliffe said to­day that R&D pres­i­dent Rafael Ama­do — a GSK vet based in their Philadel­phia fa­cil­i­ty — is on the way out to pur­sue oth­er op­por­tu­ni­ties in the in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER